Investment Rating - The investment rating for the company is maintained at "Buy" with a target price of RMB 23.23 [6][5]. Core Views - The company achieved a revenue of RMB 3.398 billion in 2025, representing a year-on-year growth of 10.7%, and a net profit attributable to the parent company of RMB 401 million, up 33.18% year-on-year [1][2]. - The company is optimistic about the future development of its microbial protein project and pet segment, which are expected to provide new growth momentum for high-quality development [1][5]. Revenue Breakdown - The revenue from the biological products segment was RMB 1.475 billion, growing by 11.4% year-on-year, accounting for 43.4% of total revenue [2]. - The pet segment saw significant growth, with revenue reaching RMB 858 million, a year-on-year increase of 24.4% [2]. - The international business segment reported revenue of RMB 127 million, with a year-on-year growth of 33.0% [2]. Profitability Analysis - The gross margin for the biological products business improved by 0.94 percentage points to 63.7%, enhancing overall profitability [3]. - The gross margin for the drug formulation and raw materials segment decreased by 1.34 percentage points to 35.3% due to intensified industry competition [3]. - The company increased its R&D investment, with R&D expenses reaching RMB 253 million, a year-on-year increase of 28.7% [3]. Strategic Initiatives - The company invested RMB 679 million to build a 60,000-ton annual production base for mycelium protein in Tianjin, which is expected to contribute approximately RMB 1.3 billion in annual revenue once fully operational [4]. - The company has obtained 19 new veterinary drug certificates in the pet sector, covering various fields such as deworming and vaccines, and has established a comprehensive supply chain covering over 14,000 medical terminals across 24 provinces [4].

Group 1: Financial Performance - The company achieved a revenue of CNY 3.398 billion, representing a year-on-year growth of 10.70% [3] - Net profit attributable to the parent company reached CNY 401 million, with a year-on-year increase of 33.18% [3] - Cost reduction exceeded CNY 90 million, with R&D investment surpassing CNY 100 million, accounting for 8.83% of revenue [3] Group 2: Business Segments and Market Position - The biological products segment accounted for 43.40% of total revenue, with a market share of 17.94% in the poultry biological products sector [3] - Revenue from the pet segment grew by 24.39%, supported by a supply chain covering over 14,000 pet medical terminals nationwide [3] - The international business generated revenue of CNY 1.27 billion, marking a year-on-year growth of 33% [3] Group 3: Strategic Initiatives - The company is focusing on "high pathogenic avian influenza vaccines" and "conventional poultry vaccines" to drive future growth in the poultry segment [4] - For the livestock segment, the company aims to enhance market share through deep collaboration with major breeding groups and optimizing product structure [4] - The establishment of a CNY 680 million mycelium protein industrialization base is underway, with plans to start trial operations in Q4 2026 [5][6] Group 4: Risk Management and Operational Efficiency - The company has implemented refined management of accounts receivable, resulting in a year-on-year decrease in accounts receivable balance [7] - A credit policy is in place to manage risks associated with overdue accounts, ensuring stable cash flow and operational health [7] Group 5: Future Plans and Investments - The company plans to establish a merger and acquisition fund focused on enhancing its core business in animal health, synthetic biology, and biomedicine [6] - The strategic positioning of the Zhongrui supply chain will transition to a comprehensive service provider for pet medical terminals, aiming to increase the proportion of self-developed pet vaccines [6]

Core Insights - The National Investment Group has invested in 118 projects in the biomanufacturing sector, amounting to 22.5 billion yuan, which has driven investments exceeding 100 billion yuan [1][4] - The "14th Five-Year Plan" emphasizes the need for forward-looking layouts in future industries, positioning biomanufacturing as a new economic growth point [1] Investment and Development - The National Investment Group's Biomanufacturing Innovation Research Institute signed a share transfer agreement with Dongsheng Biotechnology, initiating a new protein industrialization project [2] - This collaboration aims to establish a complete chain of "technology research and development + industrial implementation" in the new protein sector, enhancing the role of state-owned enterprises in technology leadership and industrial promotion [2][5] - The new protein industry, based on synthetic biology technology, aims to reform traditional protein acquisition methods through industrial microbial fermentation [2] Market Potential - The biomanufacturing industry is expected to grow from 16 trillion yuan in 2025 to 30 trillion yuan by 2030, indicating a significant market expansion [2] - New protein concepts have emerged in the context of food security and sustainable development, aiming to reduce reliance on traditional livestock farming [2] Strategic Initiatives - The State-owned Assets Supervision and Administration Commission launched initiatives focusing on 15 key industries, including biomanufacturing, to accelerate the development of emerging industries [4] - The National Investment Group is the leading entity in cultivating the biomanufacturing industry, with a registered capital of 6 billion yuan for its innovation research institute [4] - The investment strategy combines direct investment and fund management to accelerate the growth of the biomanufacturing sector [4] Industry Leadership - The National Investment Group has invested in 98 projects in the biopharmaceutical sector, totaling 18.4 billion yuan, which has attracted over 108.6 billion yuan in social capital [4] - Companies like Innovent Biologics and Kelun-Biotech, backed by the National Investment Group, have become industry leaders [4] - Dongsheng Biotechnology is recognized as a leading global enterprise in glutaminase transaminase, with a 60% market share in China and products exported to 43 countries [4]

Core Insights - Switzerland has ranked first in the global innovation index for 14 consecutive years since 2011, making it a significant source of innovation and the first strategic partner of China in innovation development and technology finance [2] - Planetary, a Swiss food technology company founded in 2021, focuses on developing mycelium protein fermentation technology to support industrial-scale biomass fermentation and provide mycelium protein raw materials [3][9] Company Overview - Planetary was co-founded by Marison Ian, who has over 40 years of experience in industrial fermentation, and David Brandes, who is also a co-founder of Peace of Meat [3] - The company offers upstream and downstream manufacturing services in the biomass fermentation and precision fermentation sectors, addressing the capacity bottleneck in the fermentation industry [7] Industry Context - Animal-based meat and dairy products account for over 20% of global greenhouse gas emissions and consume more than 30% of water resources and over 70% of agricultural land [5] - Fermentation-derived proteins are a more sustainable alternative, requiring less water and land, and producing lower greenhouse gas emissions [5] Technology and Production - Planetary utilizes proprietary BioBlocks™ fermentation technology and an AI platform for high-throughput screening and real-time monitoring of fungal strains and fermentation conditions [8] - The company’s mycelium protein has a PDCAAS (Protein Digestibility-Corrected Amino Acid Score) of 0.996, with a carbon dioxide equivalent of only 0.79 kg per kilogram of product, significantly lower than similar products [8] Market Presence - Planetary's first industrial-scale mycelium protein production facility is located in Alberg, Switzerland, which is currently the only industrial mycelium protein fermentation base in continental Europe [8] - In July 2025, Aldi Switzerland began selling new vegetarian chicken strips made from Planetary's fermented mycelium protein across 242 stores in Switzerland [9] Funding and Future Plans - In April 2022, Planetary completed a seed round financing of 7.5 million Swiss francs, led by Astanor Ventures, to initiate the construction of its flagship production facility in Switzerland [9] - The company plans to build and operate a global network of biomass fermentation capacity to overcome industry capacity bottlenecks [9]

Core Insights - Planetary is a Swiss food technology company founded in 2021, focusing on mycelium protein fermentation technology to support industrial-scale biomass fermentation and provide mycelium protein raw materials [2][5][7] Company Overview - Planetary was co-founded by Marison Ian and David Brandes, with Ian serving as Chief Scientific Officer and Brandes as CEO [2] - The company aims to address the bottleneck in biomass fermentation by providing upstream and downstream manufacturing services and selling mycelium protein as a B2B raw material for meat and dairy alternatives [7][9] Industry Context - Animal-derived meat and dairy products contribute over 20% of global greenhouse gas emissions and consume more than 30% of water resources and over 70% of agricultural land [5] - Fermentation-derived proteins are a more sustainable alternative, requiring less water and land while producing lower greenhouse gas emissions [5] Product and Technology - Mycelium protein is a whole food ingredient derived from the root structure of filamentous fungi, rich in protein, fiber, and fat, and requires fewer flavoring agents [7][8] - Planetary utilizes proprietary BioBlocks™ fermentation technology and an AI platform for high-throughput screening and real-time monitoring to produce cost-effective mycelium protein [8] - The company’s mycelium protein has a PDCAAS (Protein Digestibility-Corrected Amino Acid Score) of 0.996, with a carbon dioxide equivalent emission of only 0.79 kg per kilogram of product [8] Market Presence - Planetary's first industrial-scale mycelium protein production facility is located in Alberg, Switzerland, which is currently the only industrial mycelium protein fermentation site in continental Europe [8] - The company has begun supplying high-quality, animal-free mycelium protein to retailers, with Aldi Switzerland selling new vegetarian chicken strips made from Planetary's fermentation [9] Funding and Future Plans - In April 2022, Planetary completed a seed funding round of 7.5 million Swiss francs led by Astanor Ventures, with additional investments from XAnge, Blue Horizon, and Nucleus Capital [9] - The company plans to build and operate a global network of biomass fermentation capacities to overcome industry capacity bottlenecks [9] Recognition - Planetary is listed in the 2025 TOP100 Swiss Startups, which highlights innovative and market-potential companies in Switzerland [11]

Core Insights - The company has established a pilot production line for mycelium protein and completed the research on the pilot production process, indicating a foundation for industrialization and promotion [1] - A new production facility is currently under construction, which is expected to enhance production capacity [1] - According to the feasibility study report, once the project is fully operational, it is projected to generate an annual revenue of 1.3 billion yuan [1]

Core Insights - The Chinese biological manufacturing industry is experiencing robust growth, with a total scale nearing 1 trillion yuan and fermentation capacity accounting for over 70% of the global market [1][2] - Microbial protein represents a disruptive innovation in the food supply system, offering a more efficient and environmentally friendly alternative to traditional agriculture and livestock farming [3][4] Industry Overview - The biological manufacturing sector is characterized by the use of industrial biotechnology, leveraging microorganisms, cells, and enzymes for product production [2] - The industry is currently in a "blue ocean" phase, with less than 1% of microbial species on Earth having been discovered, indicating significant potential for resource exploration and development [2] Technological Advancements - New strains of fungi developed through large-scale industrial fermentation can yield protein content exceeding 50%, comparable to animal-derived meat in terms of nutrition and taste [1] - Synthetic biology techniques are significantly reducing the costs of pharmaceuticals, such as the production of bear bile acid substitutes, which are now much more affordable and environmentally sustainable [4][5] Environmental Impact - Microbial protein production can replace the protein generated from traditional sources like soybeans and livestock, leading to a reduction of over 90% in land, water usage, and carbon emissions [3] - The production facility for fungal protein can replace the protein output of 10,000 cattle or 24 million chickens, showcasing its environmental advantages [3] Policy and Investment - The growth of the biological manufacturing industry is supported by targeted industrial policies and patient capital, which are crucial for scaling production and fostering innovation [5][6] - The Ministry of Industry and Information Technology (MIIT) is actively promoting the application of artificial intelligence in biological manufacturing and facilitating the transition from research to industrial application [7] Collaboration and Innovation - Successful innovation in the biological manufacturing sector requires collaboration between academia and industry, with a focus on integrating research outcomes into practical applications [6][7] - The establishment of innovation centers aims to bridge the gap between basic research and industrial implementation, facilitating the transfer of scientific achievements into market-ready products [7]

【SynBioCon】 获 悉， 4月28日，主题为"技术造物 创引未来"的天津港保税区生物制造产业新闻发 布会举行。会上，天津港保税区发布了 《天津港保税区推动生物制造产业高质量发展行动方案》 （以 下简称《行动方案》）和 《天津港保税区关于支持生物制造产业高质量发展的若干政策》 （以下简 称"生物制造十条"）。 近些年，生物制造作为全新的"造物"技术，成为全球竞相布局的科技战略高地。今年政府工作报告中 提到，因地制宜发展新质生产力，培育生物制造、量子科技、具身智能、6G等未来产业。我市去年已 印发《天津市加快合成生物创新策源推动生物制造产业高质量发展实施方案》，天津港保税区按照全市 工作部署正全力打造生物制造先导区。此次发布会展现了天津港保税区生物制造产业在创新策源、成果 产业化、空间布局、人才支撑、标志性项目等方面的先发优势及推动生物制造创新成果产业化应用实 践，促进新产业、新模式、新动能加快 落地。 01 政策上新 全力打造百亿级产业集群 记者从会上获悉，《行动方案》以推动生物制造创新成果产业化应用实践为主线，因地制宜构建符合新 质生产力发展的新型生产关系，重点聚焦创新策源地、孵化转化高地和创新生态三 ...